Kidney After Nonrenal Transplantation—The Impact of Alemtuzumab Induction | Zendy

Ron Shapiro | Zendy; Amit Basu | Zendy; Henkie P. Tan | Zendy; Claire Morgan | Zendy; Vivek Sharma | Zendy; Deanna Blisard | Zendy; Parmjeet Randhawa | Zendy; Igor Dvorchik | Zendy; Jerry McCauley | Zendy; Demetrius Ellis | Zendy; J. Wallis Marsh | Zendy; Steven A. Webber | Zendy; Geoffrey Kurland | Zendy; Kenneth R. McCurry | Zendy; Kareem AbuElmagd | Zendy; George Mazariegos | Zendy; Thomas E. Starzl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Kidney After Nonrenal Transplantation—The Impact of Alemtuzumab Induction

Author(s) -

Ron Shapiro,

Amit Basu,

Henkie P. Tan,

Claire Morgan,

Vivek Sharma,

Deanna Blisard,

Parmjeet Randhawa,

Igor Dvorchik,

Jerry McCauley,

Demetrius Ellis,

J. Wallis Marsh,

Steven A. Webber,

Geoffrey Kurland,

Kenneth R. McCurry,

Kareem AbuElmagd,

George Mazariegos,

Thomas E. Starzl

Publication year - 2009

Publication title -

transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.45

H-Index - 204

eISSN - 1534-6080

pISSN - 0041-1337

DOI - 10.1097/tp.0b013e3181b4aaf5

Subject(s) - alemtuzumab , medicine , immunosuppression , kidney transplantation , transplantation , calcineurin , tacrolimus , nephrotoxicity , gastroenterology , population , urology , kidney , surgery , environmental health

Calcineurin inhibitor nephrotoxicity in nonrenal allograft recipients can lead to end-stage renal disease and the need for kidney transplantation. We sought to evaluate the role of alemtuzumab induction in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research